-+ 0.00%
-+ 0.00%
-+ 0.00%

Bristol Myers Squibb Announces FDA Priority Review And Breakthrough Therapy Designation For Iberdomide Combination Therapy In Relapsed Or Refractory Multiple Myeloma

Benzinga·02/17/2026 12:07:43
Listen to the news
  • Iberdomide has the potential to be the first approved CELMoD agent
  • The U.S. FDA has granted Breakthrough Therapy Designation and Priority Review for this indication and assigned a target action date of August 17, 2026